Quarterly ResultMay 11, 2026, 10:06 AM
BioScience Health Innovations Q1 Net Loss $(229,907); Revenue Down 38.7%
AI Summary
BioScience Health Innovations reported a net loss of $(229,907) in Q1 2026, a significant decline from a net income of $426,798 in Q1 2025, with revenue also decreasing by 38.7%. Despite the financial downturn, the company maintains a strong cash position of $1,145,005 and positive net working capital, believing it has sufficient liquidity for the next year. Strategically, the company is optimistic about its patent-pending Methylene Blue products and the potential market expansion from the expected FDA reclassification of several peptides to Category 1, which could create immediate commercial opportunities for its oral peptide delivery platform.
Key Highlights
- Q1 2026 net loss was $(229,907) compared to net income of $426,798 in Q1 2025.
- Q1 2026 revenue decreased 38.7% to $750,946 from $1,227,070 in Q1 2025.
- Cash and cash equivalents increased to $1,145,005 as of March 31, 2026.
- Net cash used in operating activities was $(552,107) in Q1 2026.
- FDA expected to reclassify 14 of 19 restricted peptides to Category 1, expanding market.
- Issued 437,067 common shares for $437,067 cash in Q1 2026.
- Entered a $460,402 promissory note for related party debt.
- Inventory increased to $874,340 as of March 31, 2026.